While GLP-1 drugs are currently available in the market, the Food and Drug Administration (FDA) had declared a shortage of semaglutide supply since 2022 after its popularity skyrocketed following news ...

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

What about the side-effects? Will I regain all my weight? Dr Sarah Jarvis has the answers to your burning questions.

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...

The FDA has declared that the shortage of popular weight-loss drugs, including Ozempic and Wegovy, is officially over.

With rumours circulating that Selena Gomez and other celebrities have used Ozempic, we reached out to experts to understand ...

The weight loss drug market is booming, with GLP-1 medications projected to hit $100 billion by 2030. These drugs, which help ...

Semaglutide may help reduce alcohol cravings and intake, according to a clinical trial. Participants receiving the drug drank ...

For Oscars 2025, there's a new trend in town: microdosing, taking tiny amounts of Ozempic and other weight-loss jabs is the ...

Hims & Hers' lower-priced injectable semaglutide promoted during the Super Bowl has led to some patients receiving the more ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...